Form 4: Immunocore Holdings Executive Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
David M. Berman, Head of R&D at Immunocore Holdings plc, executed sales of ordinary shares on February 26 and 27, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- David M. Berman, Head of R&D at Immunocore Holdings plc, reported the sale of ordinary shares on February 26 and 27, 2024.
- The sales were executed under a Rule 10b5-1 trading plan adopted on March 6, 2023.
- On February 26, 2024, Berman acquired 28,553 shares through option exercise at a price of $17.46 and sold 28,553 shares in multiple transactions at weighted average prices of $70.6 and $71.31.
- On February 27, 2024, Berman acquired 54,938 shares through option exercise at a price of $17.46 and sold 54,938 shares in multiple transactions at weighted average prices ranging from $69.45 to $71.97.
- Following these transactions, Berman directly owns 308,299 ordinary shares.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports transactions under a pre-arranged trading plan. There is no indication of positive or negative news about the company.
Industry Context
This filing is a routine disclosure of insider trading activity. It is common for executives to use 10b5-1 plans to sell shares over time to avoid accusations of trading on inside information. The activity itself doesn't necessarily indicate a positive or negative outlook for the company.
Comparison to Industry Standards
- Executive share sales are a common occurrence in publicly traded companies, particularly in the biotechnology sector.
- The use of a 10b5-1 trading plan is a standard practice to ensure compliance with insider trading regulations.
- Comparable companies such as Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also see regular Form 4 filings related to executive stock transactions.
Key Dates
| Date | Description |
|---|---|
| 2023/03/06 | Date of adoption of Rule 10b5-1 trading plan |
| 2024/02/26 | Date of first transaction: acquisition and disposition of shares |
| 2024/02/27 | Date of second transaction: acquisition and disposition of shares |
| 2024/02/28 | Date of signature of the Form 4 filing |
| 2028/09/12 | Expiration date of Employee Share Option |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.